Hotline: 1800 102 2007
X
Search Business Opportunities
Feb, 28 2018

Roche and Cipla to Jointly market anti cancer drugs

The partnership is in line with Roche and Cipla’s efforts to improve healthcare and increase access to innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.

Rivals in the past, Swiss drug maker Roche Pharma and India’s third-largest drug maker have combined to promote and distribute tocilizumab (Actemra) and Syndyma, the 2nd brand of Roche’s cancer therapy, bevacizumab (Avastin) in India.

In a joint statement, the company said this partnership is in line with Roche and Cipla’s efforts to improve healthcare and increase access to innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.

Lara Bezerra, Managing Director, Roche Pharma India said, “We believe that everyone who needs our medicines should be able to access and benefit from them. This partnership will significantly advance our efforts to expand the reach of, and improve access to, our innovative medicines.”

Roche said this partnership will also help us to cater to Indian Patients by bringing new, transformative medicines to them. The company said it we will continue to collaborate with various stakeholders to help transform healthcare in India.

Bevacizumab is a recombinant humanised monoclonal antibody that selectively binds to and neutralises the biologic activity of human vascular endothelial growth factor (VEGF). Various clinical trials have proven its efficacy and safety in different solid tumours and are approved by regulators worldwide for certain type of a brain tumour, cancers of the kidney, lung, colon and rectum and certain types of gynaecological cancers viz. ovarian cancer and cervical cancers. It is usually given as part of a combination of cancer medicines.

Actemra(tocilizumab Injection) is a recombinant humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody. This IL-6 protein is believed to play an important role in RA. Studies have shown the drugs work in treating rheumatoid arthritis.

For Roche the entry of biosimilar drugs or the high end copy versions of its biologic drugs has eaten into its revenues. However India with its vast disease profile continues to be an important market for the company. For Cipla that had built its business by challenging the patents of multinational companies, the new business strategy is to adopt more of a collaborative effort with its past rivals. A few years back Cipla also entered into a voluntary license agreement with US drugmaker Gilead to market its Hepatitis C drugs.

Comment
image
Related opportunities
  • Catering
    About Us: Established in 1989, Lajawab Culinary Art is a premium..
    Locations looking for expansion Delhi
    Establishment year 1989
    Franchising Launch Date 2018
    Investment size Rs. 1 Cr. - 2 Cr
    Space required 6000
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater New delhi Delhi
  • Online learning/E-learning
    About Us: Partnership Opportunity- Franchise partner plays a crucial role in our..
    Locations looking for expansion Maharashtra
    Establishment year 2015
    Franchising Launch Date 2019
    Investment size Rs. 50 K - 2lac
    Space required -NA-
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Mumbai Maharashtra
  • Locations looking for expansion -NA-
    Establishment year -NA-
    Franchising Launch Date -NA-
    Investment size
    Space required 200
    Franchise Outlets -NA-
    Franchise Type -NA-
    Headquater
  • Quick Service Restaurants
    About Us: There is one inexhaustible aspect of everyday life that..
    Locations looking for expansion Delhi
    Establishment year 2018
    Franchising Launch Date 2018
    Investment size Rs. 20lac - 30lac
    Space required -NA-
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater New delhi Delhi
Insta-Subscribe to
The Franchising World
Magazine
For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you
OR Click here to Subscribe Online
Daily Updates
Submit your email address to receive the latest updates on news & host of opportunities